A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia
Phase of Trial: Phase II
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Idarubicin (Primary) ; Cytarabine; Decitabine; Filgrastim; Fludarabine
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 12 Jun 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
- 02 May 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
- 06 Apr 2015 Planned End Date changed from 1 Apr 2016 to 1 Apr 2017 as reported by ClinicalTrials.gov record.